Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
QScreen AI Inc. develops artificial-intelligence health screening technology for clinical, correctional, occupational, and institutional settings. Company news centers on the QAI Platform, which combines physiological signals from a standard camera, passive voice analysis, and structured clinical intake workflows to support real-time screening and documented intake outputs.
Recurring updates cover platform integration, internal validation work, patent activity, commercialization efforts in North American institutional and workforce markets, strategic advisory and contractor relationships, and financing actions tied to deployment and working capital. The company also reports on clinical instruments used within its intake workflows, including CIWA-Ar, COWS, and C-SSRS.
QScreen AI (OTC: PMEDF) announced integration of a passive voice analysis engine into its multi-signal screening platform on May 6, 2026. The system now reads physiological, acoustic, and behavioral signals simultaneously using existing device microphones and camera data, with individualized longitudinal baselining and no added hardware or workflow changes.
The platform measures voice features such as response latency, speech rate, vocal tremor and pitch against each person’s prior baseline, and is positioned for correctional intake, pre-shift fitness-for-duty screening and addiction rehabilitation deployments.
QScreen AI (OTC: PMEDF) reported internal validation of its correctional intake platform across 65 calibrated clinical scenarios, validating nine instruments versus published thresholds. Key results include 100% sensitivity and specificity for Columbia C-SSRS suicide risk and CIWA-Ar/COWS withdrawal, plus an active 60-day pilot plan and no specialized hardware required for deployment.
QScreen AI (OTC: PMEDF) appointed José Humberto "Beto" Vargas García as Strategic Advisor to accelerate entry into North American rail and transportation markets. Mr. Vargas brings 25 years of senior commercial relationships across Class I railroads and former Vice President experience at Union Pacific, managing a USD $2.8 billion commercial portfolio. The company says its QAI Platform uses camera-captured physiological signals to identify probable drug use in real time without blood, breath, or urine samples. The release also notes a change of auditor.
QScreen AI (OTC:PMEDF) completed its patent‑protected QAI physiological AI clinical platform that identifies probable substance class (alcohol, opioid, benzodiazepine, stimulant, cannabis) from a standard laptop camera and runs 13 validated clinical instruments in under seven minutes with no hardware or IT project.
The platform processed >720,000 real‑world scans and the company is pursuing evaluation agreements with correctional health and US defense verticals, targeting a 300–500 facility pipeline while engaging Global Frontier Advisors led by Lt. Gen. Michael S. Groen (Ret.).
QScreen AI (OTC Pink: PMEDF) announced a non‑brokered private placement to issue up to 10,000,000 units at C$0.05 per Unit for aggregate gross proceeds of up to C$500,000. Each Unit includes one common share and one half warrant; each warrant allows purchase of one half share at C$0.15 for 36 months.
Proceeds will fund structured pilot discussions, operational integration planning and working capital to scale commercialization across healthcare, industrial and technology sectors, building on recent trade mission activity in Mexico.
QScreen AI (OTC: PMEDF) reported substantive commercialization discussions during the Government of Canada trade mission to Mexico on February 23, 2026. The company held structured one-on-one meetings across healthcare, defense, advanced manufacturing, agri-food, infrastructure, and AI ecosystems.
Discussions advanced to defined follow-up talks to shape pilot scope, deployment parameters, and integration requirements; definitive agreements remain subject to customary commercial evaluation and approvals. The company noted a recent U.S. patent filing and said Mexico represents a sizable addressable opportunity for enterprise-scale Quantum-AI screening solutions.
QScreen AI (OTC Pink: PMEDF) filed a U.S. provisional patent (Application 63/981,576) for a "Quantum-Inspired Multi-Objective Optimization" platform aimed at clinical intake and readiness workflows.
The filing, highlighted during national CBC coverage, emphasizes solver-agnostic quantum-inspired algorithms, robotic deployments, surge-responsive controls, and commercial focus on defense, public safety, and enterprise screening.
QScreen AI (OTC Pink: PMEDF) announced an independent contractor agreement with Global Frontier Advisors L.P., effective January 30, 2026. The engagement will use equity and performance-based compensation, pending regulatory and exchange approvals.
The mandate targets commercialization and business development across correctional, institutional, industrial, defense, and large-event public-safety settings, led by managing partner Lieutenant General Michael S. Groen (Ret.), aiming to expand QScreen AI's U.S. and international presence for preemptive health surveillance and workplace safety.
QScreen AI Inc. (OTC: PMEDF; CSE: QAI) completed a formal name change from Predictmedix AI to QScreen AI effective on or about January 27, 2026. The change does not affect share capital, business operations, management, or strategic direction.
The company issued a new CUSIP 746960103 and ISIN CA7469601032, and expects Common Shares to trade under the new CSE symbol QAI at market open. QScreen AI says it is evolving from single-application screening to a broader decision-intelligence platform that integrates quantum-inspired and advanced computational techniques with classical machine learning to improve detection, speed, and scalability and to support commercialization across healthcare, safety, and adjacent markets.
Predictmedix (OTC: PMEDF) was selected for the Official Canada Trade Mission to Mexico, Feb 15–20, 2026, led by Minister Dominic LeBlanc. The company gains government‑facilitated introductions to Mexican distributors, clients, and industry leaders across Mexico City, Guadalajara, and Monterrey to accelerate market entry and revenue opportunities.
Predictmedix will access sector briefings, strategic site visits, and concierge support from the Trade Commissioner Service, while highlighting quantum‑inspired algorithm integration and plans to onboard regional distribution leadership to drive LATAM commercialization.